BD INSYTE™ AUTOGUARD™ BC

Transcription

BD INSYTE™ AUTOGUARD™ BC
BD INSYTE AUTOGUARD BC
™
™
with blood control technology
All the familiar sizes of BD Insyte Autoguard, now with Blood Control Technology
BD Insyte™ Autoguard™ BC
Product Information
Non-Winged
Winged
382512
382612
382523
Gauge
Length
Flow Rate
Catheter OD
Catheter ID
Units Box/Case
24
0.75 in. (0.7 mm x 19 mm)
20 mL/min
.026 in.-.029 in. (0.66-0.74 mm)
.019 in.-.022 in. (0.48-0.56 mm)
50/200
382623
22
1.00 in. (0.9 mm x 25 mm)
37 mL/min
.033 in.-.036 in. (0.84-0.91 mm)
.024 in.-.027 in. (0.61-0.69 mm)
50/200
382533
382633
20
1.00 in. (1.1 mm x 25 mm)
63 mL/min
.041 in.-.044 in. (1.04-1.12 mm)
.030 in.-.033 in. (0.76-0.84 mm)
50/200
382534
382634
20
1.16 in. (1.1 mm x 30 mm)
61 mL/min
.041 in.-.044 in. (1.04-1.12 mm)
.030 in.-.033 in. (0.76-0.84 mm)
50/200
382537
382637
20
1.88 in. (1.1 mm x 48 mm)
54 mL/min
.041 in.-.044 in. (1.04-1.12 mm)
.030 in.-.033 in. (0.76-0.84 mm)
50/200
382544
382644
18
1.16 in. (1.3 mm x 30 mm)
95 mL/min
.050 in.-.053 in. (1.27-1.35 mm)
.037 in.-.040 in. (0.94-1.02 mm)
50/200
382547
382647
18
1.88 in. (1.3 mm x 48 mm)
87 mL/min
.050 in.-.053 in. (1.27-1.35 mm)
.037 in.-.040 in. (0.94-1.02 mm)
50/200
382554
382654
16
1.16 in. (1.7 mm x 30 mm)
193 mL/min
.067 in.-.070 in. (1.70-1.78 mm)
.052 in.-.055 in. (1.32-1.40 mm)
50/200
382557
382657
16
1.77 in. (1.7 mm x 45 mm)
185 mL/min
.067 in.-.070 in. (1.70-1.78 mm)
.052 in.-.055 in. (1.32-1.40 mm)
50/200
Making safety safer
The 18 to 22 gauge catheters are capable of withstanding high-pressure injection procedures.
To order or learn more about BD Insyte™ Autoguard™ BC,
call 1.888.237.2762 or visit www.bd.com/IAGBC
1Onia R, Eshun-Wilson I, Arce C, et al. Evaluation of a new safety peripheral IV catheter designed
to reduce mucocutaneous blood exposure. Curr Med Res Opin. 2011;27(7):1339-1346.
* comparison to a traditional peripheral IV catheter
2 Jagger J, Perry J, Parker G, et al. Blood exposure risk during peripheral I.V. catheter insertion
and removal. Nursing. 2011;41(12):45-49.
3 Richardson D, Kaufman L. Reducing blood exposure risks and costs associated with SPIVC
insertion. Nurs Manage. 2011;42(12):31-34.
4Mendelson MH, Lin-Chen BY, Finkelstein-Blond L, Bailey E, Kogan G. Evaluation of a safety IV
catheter (IVC) (Becton Dickinson, Insyte Autoguard): final report [abstract]. Eleventh Annual
Scientific Meeting Society for Healthcare Epidemiology of America. 2001.
** comparison to a non-safety peripheral IV catheter
5Gaukroger PB, Roberts JG, Manners TA. Infusion thrombophlebitis: a prospective comparison
of 645 Vialon and Teflon cannulae in anaesthetic and postoperative use.
Anaesthesia and Intensive Care. 1988;16:265-271.
6Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous
catheters. Annals of Internal Medicine. 1991;114:845-854.
BD, BD Logo, and all other trademarks are property of Becton, Dickinson and Company.
© 2013 BD. Printed in the USA
BD Medical
9450 South State Street
Sandy, Utah 84070
1.888.237.2762
www.bd.com/IAGBC
MSS0258-1B (1/13)
SM
BD Insyte™
Autoguard™ BC:
clinically shown to
reduce the risk of
blood exposure
by 95% *
Making safety safer for you
Standard non-blood-control IV catheter
1
The healthcare industry has come a long way in
preventing needlestick injuries and their potential
dangers. Even so, blood exposure during a peripheral
IV insertion is still a factor—and a risk—to healthcare
workers and patients.
Reduce Cross-Contamination Risks
Because there is dramatically less blood leakage at
insertion, BD Insyte™ Autoguard™ BC can mean less
potential cross contamination. Minimizing spills means
there’s less blood to get on gloves, clothing, shoes,
bedding, floors, or equipment.1
Study Data
• A
study shows the rate of at-risk blood exposure for
IV catheter insertions is 128 per 100,000 insertions
(this is the combined rate of blood contact to the
eyes, nose, mouth, and nonintact skin).2
• A
study shows that while placing a peripheral IV
catheter, clinicians often use gauze, absorbent drape,
towels or sheets.3
• A study shows the average cost per cleanup for these materials is $0.30 per insertion.3
BD Blood Control Technology—designed to stop blood so it doesn’t escape the hub. Controlling blood escape means a cleaner area helping to increase patient confidence.
Clinically Demonstrated
Now blood exposure doesn’t have to be
“part of the job.” In a clinical study, 98% of
clinicians stated they had no risk of blood
exposure during insertion when using
BD Insyte Autoguard BC,1* which means:
NEW
• New blood-control technology shown to reduce
the risk of blood exposure by 95%.1*
BD Blood Control Technology
• Push-button shielding technology proven to
reduce needlestick injuries by 95%.4**
• BD Vialon™ biomaterial—is designed to soften in the
vein and provides greater kink resistance5 and longer
dwell time6 compared to FEP polymer.
• Less risk of exposure to bloodborne pathogens.
• Virtually no clean up of blood spills.
• No need to worry about stopping blood.1
BD Instaflash™ Needle Technology
Push-button Needle Shielding
Safety Beyond Needlestick Protection
• Virtually no blood leakage and immediate cost
savings on clean-up supplies.
BD Insyte™ Autoguard™ BC IV catheters are a part
of the BD Medical family of products—products that
reflect a continuing commitment to keeping healthcare workers safer worldwide. To order or request
more information, call 1.888.237.2762 or
visit www.bd.com/IAGBC
“Because one blood droplet found my eye, I was at risk.”
c h ery l l co l l ins ,
bsn , rn , ocn
View Cheryll’s and
other blood exposure
stories online at
www.bd.com/
bloodcontrol
BD Vialon™ Biomaterial
Complete Needle Encapsulation

Similar documents

Closed IV Catheter - B. Braun Medical Inc.

Closed IV Catheter - B. Braun Medical Inc. • Cut costs by reducing needlesticks and cleanup time and materials.

More information

Global Market Study on Peripheral Intravenous Catheter Market, 2015-2021

Global Market Study on Peripheral Intravenous Catheter Market, 2015-2021 The global peripheral intravenous catheter market was valued at US$ 3,500 Mn in 2014. North America was the largest market for peripheral intravenous catheters, accounting for over 45% revenue share of the overall market in 2014, followed by Europe with around 27% share. Moreover, Asia-Pacific market is expected to exhibit highest CAGR of 6.7% during the forecast period (2015–2021), followed by the North America. Factors such as increasing per capita healthcare spending, increasing aging population, increase in a number of diseases, and advancement in PIVC technology are expected to support a growth of the peripheral intravenous catheter market over the forecast period.

More information

Peripheral I.V. Catheter Market Analysis and Demand Forecast to 2022

Peripheral I.V. Catheter Market Analysis and Demand Forecast to 2022 The global peripheral I.V. catheter market was valued at $3,702.2 million in 2015, and it is expected to grow at a CAGR of 6.0% during the period 2016 - 2022. The global market is increasing, due to growing geriatric population and increasing incidence of chronic diseases. In addition, the growing demand for injectable drugs in comparison to the oral medications, increasing healthcare expenditure and technological advancements in peripheral I.V. catheter is encouraging the growth of the global peripheral I.V. catheter market.

More information